Smallpox vaccines for biodefense

Vaccine

Volumn 27, Issue SUPPL. 4, 2009, Pages

  Kennedy, Richard B ^a   Ovsyannikova, Inna ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Biodefense; Smallpox vaccine; Vaccinia virus; Variola virus

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; INACTIVATED VACCINE; LIVE VACCINE; SMALLPOX VACCINE; SUBUNIT VACCINE; VACCINIA VACCINE;

ANTIVIRAL ACTIVITY; ARTICLE; BIOLOGICAL WARFARE; DRUG FEVER; ECZEMA; ENCEPHALITIS; FATIGUE; HEADACHE; HUMAN; IMMUNE RESPONSE; LYMPHADENOPATHY; MYALGIA; NAUSEA; NONHUMAN; PATHOLOGY; PERICARDITIS; PRIORITY JOURNAL; PRURITUS; SMALLPOX; TISSUE CULTURE; UNSPECIFIED SIDE EFFECT;

EID: 78149416888     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.103     Document Type: Article

References (128)

1. Dixon CW. Smallpox. London: J&A Churchill; 1962.
2. FennerDAHF, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva: WHO; 1988.
3. Jenner E. An inquiry into the causes and effects of the variolae vaccinae, a disease discovered in some of the western counties of England, particularly Gloucestershire and known by the name of the cow pox. London: Law; 1798.
4. Cook GC. The smallpox saga and the origin(s) of vaccination. J Royal Soc Health 1996;116(4):253-5.
5. Fenner F. A successful eradication campaign. Global eradication of smallpox. Rev Infect Dis 1982;4(September-October(5)):916-30.
6. Fenner F. The global eradication of smallpox. Med J Aust 1980;1(May(10)): 455-65.
7. Wehrle PF, Posch J, Richter KH, Henderson DA. An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull World Health Organ 1970;43(5):669-79.
8. Neff JM, Lane JM, Fulginiti VA. Smallpox and smallpox vaccination. N Engl J Med 2003;348(May(19)):1920-5 [author reply -5].
9. Moore ZS, Seward JF,;1; Lane JM. Smallpox. Lancet 2006;367(February(9508)): 425-35.
10. Fenn EA. Pox Americana: the great smallpox epidemic of 1775-82. 1st ed. New York: Hill and Wang; 2001.
11. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003;9(9):1131-7.
12. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003;171(November(10)):4969-73.
13. Combadiere B, Boissonnas A, Carcelain G, Lefranc E, Samri A, Bricaire F, et al. Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med 2004;199(June(11)):1585-93.
14. Amanna IJ, Slifka MK, Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol Rev 2006;211:320-37.
15. Frey SE, Newman FK, Yan L, Lottenbach KR, Belshe RB. Response to smallpox vaccine in persons immunized in the distant past. JAMA 2003;289(June(24)):3295-9.
16. Kim SH, Choi SJ, Park WB, Kim HB, Kim NJ, Oh MD, et al. Detailed kinetics of immuneresponses to anewcell culture-derived smallpox vaccine in vaccinianaive adults. Vaccine 2007;25(August(33)):6287-91.
17. Taub DD, Ershler WB, Janowski M, Artz A,;1; Key ML, McKelvey J, et al. Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med 2008;121(12):1058-64.
18. Ferrier-Rembert A, Drillien R, Tournier JN, Garin D, Crance JM. Short- and longterm immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine 2008;26(March(14)):1794-804.
19. Hopkins RJ, Lane JM. Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. Clin Infect Dis 2004;39(September(6)):819-26.
20. Bray M, Martinez M, Smee DF, Kefauver D, Thompson E, Huggins JW. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis 2000;181(1):10-9.
21. Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004;318(January(2)):474-81.
22. Smee DF,;1; Bailey KW, Wong MH, Sidwell RW. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res 2001;52(1):55-62.
23. Whitley RJ. Smallpox: a potential agent of bioterrorism. Antiviral Res 2003;57(1-2):7-12.
24. Leitenberg M. Production and use of biological weapons: need for international sanctions? JAMA 1997;278(August(5)):387-8.
25. Guillemin J. Biological weapons and secrecy (WC 2300). Faseb J 2005;19(13):1763-5.
26. Henderson DA. The looming threat of bioterrorism. Science 1999;283(February(5406)): 1279-82.
27. Fenner F. Smallpox and its eradication. Geneva: World Health Organization; 1988.
28. Mack TM,;1; Noble Jr J, Thomas DB. A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg 1972;21(2):214-8.
29. Sarkar JK, Mitra AC, Mukherjee MK. The minimum protective level of antibodies in smallpox. Bull World Health Organ 1975;52(3):307-11.
30. Lane JM, Ruben FL, Abrutyn E, Millar JD. Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968. JAMA 1970;212(April(3)):441-4.
31. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970;122(4): 303-9.
32. Halsell JS, Riddle JR, Atwood JE, Gardner P, Shope R, Poland GA, et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 2003;289(June(24)):3283-9.
33. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review. Part II. Adverse events. Clin Infect Dis 2003;37(July(2)):251-71.
34. Arita I. Smallpox vaccine and its stockpile in 2005. Lancet Infect Dis 2005;5(10):647-52.
35. Smith BT, Inglesby TV, Brimmer E, Borio L, Franco C, Gronvall GK, et al. Navigating the storm: report and recommendations from the Atlantic Storm exercise. Biosecur Bioterror 2005;3(3):256-67.
36. Neff J, Modlin J, Birkhead GS, Poland G, Robertson RM, Sepkowitz K, et al. Monitoring the safety of a smallpox vaccination program in the United States: report of the joint Smallpox Vaccine Safety Working Group of the advisory committee on immunization practices and the Armed Forces Epidemiological Board. Clin Infect Dis 2008;46(March(Suppl. 3)):S258-70.
37. Poland GA, Grabenstein JD, Neff JM. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 2005;March(23)(17-18):2078-81.
38. Rosenthal SR, Merchlinsky M, Kleppinger C, Goldenthal KL. Developing new smallpox vaccines. Emerg Infect Dis 2001;7(November-December(6)): 920-6.
39. Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, Newman FK, et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002;346(April(17)):1265-74.
40. Talbot TR, Stapleton JT, Brady RC, Winokur PL, Bernstein DI, Germanson T, et al. Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial. JAMA 2004;292(September(10)):1205-12.
41. Gassmann R, Engler OB, Steffen R, Alex M, Czerny CP, Mutsch M. Clinical and immuneresponse to undiluted and diluted smallpox vaccine. Swiss Med Wkly 2008;138(July(27-28)):392-7.
42. Couch RB, Winokur P, Edwards KM, Black S, Atmar RL, Stapleton JT, et al. Reducing the dose of smallpox vaccine reduces vaccine-associated morbidity without reducing vaccination success rates or immune responses. J Infect Dis 2007;195(March(6)):826-32.
43. Hsieh SM, Chen SY, Sheu GC, Hung MN, Chou WH, Chang SC, et al. Clinical and immunological responses to undiluted and diluted smallpox vaccine with vaccinia virus of Lister strain. Vaccine 2006;24(January(4)):510-5.
44. Gouvras G. Policies in place throughout the world: action by the European Union. Int J Infect Dis 2004;8(Suppl. 2):S21-30.
45. Monath TP, Caldwell JR, Mundt W, Fusco J, Johnson CS, Buller M, et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)-a second-generation smallpox vaccine for biological defense. Int J Infect Dis 2004;8(Suppl. 2):S31-44.
46. Osborne JD,;1; Da Silva M, Frace AM, Sammons SA, Olsen-Rasmussen M, Upton C, et al. Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3. Vaccine 2007;25(December(52)):8807-32.
47. Frey SE, Newman FK, Kennedy JS, Ennis F, Abate G, Hoft DF, et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax((R)) in healthy vaccinia-naive adults. Vaccine 2008;December.
48. Artenstein AW, Johnson C, Marbury TC, Morrison D, Blum PS, Kemp T, et al. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine 2005;23(May(25)):3301-9.
49. Marriott KA, Parkinson CV, Morefield SI, Davenport R, Nichols R, Monath TP. Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine 2008;26(January(4)):581-8.
50. Greenberg RN, Kennedy JS. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs 2008;17(4): 555-64.
51. Metzger W, Mordmueller BG. Vaccines for preventing smallpox. Cochrane database of systematic reviews (online) 2007(3):CD004913.
52. Parrino J, Graham BS. Smallpox vaccines: past, present, and future. J Allergy Clin Immunol 2006;118(6):1320-6.
53. Poland GA. Smallpox vaccines: from first to second to third generation. Lancet 2005;365(January-February(9457)):362-3.
54. Artenstein AW, Grabenstein JD. Smallpox vaccines for biodefense: need and feasibility. Expert Rev Vaccines 2008;7(8):1225-37.
55. Murphy FA, Osburn BI. Adventitious agents and smallpox vaccine in strategic national stockpile. Emerg Infect Dis 2005;11(7):1086-9.
56. Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS, et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med 2003;9(9):1125-30.
57. Greenberg RN, Kennedy JS, Clanton DJ, Plummer EA, Hague L, Cruz J, et al. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet 2005;365(January-February(9457)):398-409.
58. Wiser I, Balicer RD, Cohen D. An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies. Vaccine 2007;25(January(6)):976-84.
59. Sugimoto M, Yamanouchi K. Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines. Vaccine 1994;12(8):675-81.
60. KidokoroM, TashiroM, Shida H. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc Natl Acad Sci USA 2005;102(March(11)):4152-7.
61. Empig C, Kenner JR, Perret-Gentil M, Youree BE, Bell E, Chen A, et al. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine 2006;24(April(17)):3686-94.
62. Mayr A, Stickl H, Muller HK, Danner K, Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl). Zentralbl Bakteriol [B] 1978;167(5-6):375-90.
63. Mayr A. Historical review of smallpox, the eradication of smallpox and the attenuated smallpox MVA vaccine. Berl Munch Tierarztl Wochenschr 1999;112(9):322-8.
64. Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006;24(March(12)):2065-70.
65. Kennedy JS, Greenberg RN. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 2009;8(1):13-24.
66. Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 2007;25(February(8)):1513-25.
67. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992;188(1):217-32.
68. Tartaglia J, Cox WI, Pincus S, Paoletti E. Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC. Dev Biol Stand 1994;82:125-9.
69. Midgley CM, Putz MM, Weber JN, Smith GL. Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J Gen Virol 2008;89(Pt 12):2992-7.
70. Paoletti E, Tartaglia J, Taylor J. Safe and effective poxvirus vectors-NYVAC and ALVAC. Dev Biol Stand 1994;82:65-9.
71. Edghill-Smith Y, Venzon D, Karpova T, McNally J, Nacsa J, Tsai WP, et al. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J Infect Dis 2003;188(October(8)):1181-91.
72. Holzer GW, Remp G, Antoine G, Pfleiderer M, Enzersberger OM, Emsenhuber W, et al. Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression. J Virol 1999;73(6):4536-42.
73. Ober BT, Bruhl P, Schmidt M, Wieser V, Gritschenberger W, Coulibaly S, et al. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara. J Virol 2002;76(15):7713-23.
74. Coulibaly S, Bruhl P, Mayrhofer J, Schmid K, Gerencer M, Falkner FG. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 2005;341(October(1)):91-101.
75. Tagaya I, Amano H, Komatsu T, Uchida N, Kodama H. Supplement to the pathogenicity and immunogenicity of an attenuated vaccinia virus, strain DIs, in cynomolgus monkeys. Jap J Med Sci Biol 1974;27(4):215-28.
76. Tagaya I, Amano H, Yuasa T. Improved plaque assay of a mutant of vaccinia virus, strain DIs, in chick embryo cell cultures. Jap J Med Sci Biol 1974;27(4):245-7.
77. Ishii K, Ueda Y, Matsuo K, Matsuura Y, Kitamura T, Kato K, et al. Structural analysis of vaccinia virus DIs strain: application as a new replication-deficient viral vector. Virology 2002;302(October(2)):433-44.
78. OkamuraT, SomeyaK, Matsuo K, Hasegawa A, Yamamoto N, Honda M. Recombinant vaccinia DIs expressing simian immunodeficiency virus gag and pol in mammalian cells induces efficient cellular immunity as a safe immunodeficiency virus vaccine candidate. Microbiol Immunol 2006;50(12):989-1000.
79. Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, Horibata S, et al. Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J Virol 2005;79(20):12871-9.
80. Mizutani T, Fukushi S, Ishii K, Sasaki Y, Kenri T, Saijo M, et al. Mechanisms of establishment of persistent SARS-CoV-infected cells. Biochem Biophys Res Commun 2006;347(August(1)):261-5.
81. Buller RM, Smith GL, Cremer K, Notkins AL, Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985;317(October-November(6040)): 813-5.
82. Vijaysri S, Jentarra G, Heck MC, Mercer AA, McInnes CJ, Jacobs BL. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination. Vaccine 2008;26(January(5)): 664-76.
83. Rodriguez D, Rodriguez JR, Rodriguez JF, Trauber D, Esteban M. Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. Proc Natl Acad Sci USA 1989;86(4):1287-91.
84. Verardi PH, Jones LA, Aziz FH, Ahmad S, Yilma TD. Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity. J Virol 2001;75(1):11-8.
85. Zhu W, Fang Q, Zhuang K, Wang H, Yu W, Zhou J, et al. The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes. J Virol Methods 2007;144(1-2):17-26.
86. Legrand FA, Verardi PH, Jones LA, Chan KS, Peng Y, Yilma TD. Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes. J Virol 2004;78(6):2770-9.
87. Dai K, Liu Y, Liu M, Xu J, Huang W, Huang X, et al. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine 2008;26(September(39)):5062-71.
88. Reading PC, Smith GL. Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J Virol 2003;77(18):9960-8.
89. Suter M, Meisinger-Henschel C, Tzatzaris M, Hulsemann V, Lukassen S, Wulff NH, et al. Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain. Vaccine 2009;June.
90. Amies CR. Loss of immunogenic properties of vaccinia virus inactivated by formaldehyde. Can J Microbiol 1961;7:141-52.
91. Turner GS, Squires EJ, Murray HG. Inactivated smallpox vaccine. A comparison of inactivation methods. J Hyg (Lond) 1970;68(2):197-210.
92. Madeley CR. The immunogenicity of heat-inactivated vaccinia virus in rabbits. J Hyg (Lond) 1968;66(1):89-107.
93. Boulter EA, Zwartouw HT, Titmuss DH, Maber HB. The nature of the immune state produced by inactivated vaccinia virus in rabbits. Am J Epidemiol 1971;94(6):612-20.
94. Appleyard G, Hapel AJ, Boulter EA. An antigenic difference between intracellular and extracellular rabbitpox virus. J Gen Virol 1971;13(1):9-17.
95. Moss B. Poxvirus entry andmembranefusion. Virology 2006;344(January(1)): 48-54.
96. Smith GL, Vanderplasschen A, Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 2002;83(Pt 12):2915-31.
97. Galmiche MC, Goenaga J, Wittek R, Rindisbacher L. Neutralizing and;1; protective antibodies directed against vaccinia virus envelope antigens. Virology 1999;254(February(1)):71-80.
98. Davies DH, McCausland MM, Valdez C, Huynh D, Hernandez JE, Mu Y, et al. Vaccinia virus H3L envelope protein is amajor target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol 2005;79(18):11724-33.
99. Hooper JW, Custer DM, Schmaljohn CS, Schmaljohn AL. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 2000;266(January(2)):329-39.
100. Wolffe EJ, Vijaya S, Moss B. A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology 1995;211(August(1)):53-63.
101. Hooper JW, Thompson E, Wilhelmsen C, Zimmerman M, Ichou MA, Steffen SE, et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol 2004;78(9):4433-43.
102. Dean HJ, Haynes J, Schmaljohn C. The role of particle-mediated DNA vaccines in biodefense preparedness. Adv Drug Deliv Rev 2005;57(June(9)):1315-42.
103. Fogg C, Lustig S, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol 2004;78(19):10230-7.
104. Xiao Y, Aldaz-Carroll L, Ortiz AM, Whitbeck JC, Alexander E, Lou H, et al. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 2007;25(January(7)):1214-24.
105. Hooper JW, Custer DM, Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 2003;306(February(1)):181-95.
106. Heraud JM, Edghill-Smith Y, Ayala V, Kalisz I, Parrino J, Kalyanaraman VS, et al. Subunit recombinant vaccine protects against monkeypox. J Immunol 2006;177(August(4)):2552-64.
107. Golden JW, Hooper JW. Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine. Virology 2008;377(July(1)):19-29.
108. Aldaz-Carroll L, Xiao Y,;1; Whitbeck JC, de Leon MP, Lou H, Kim M, et al. Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6. J Virol 2007;81(15):8131-9.
109. Sakhatskyy P, Wang S, Zhang C, Chou TH, Kishko M, Lu S. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Virology 2008;371(February(1)):98-107.
110. Tscharke DC, Karupiah G, Zhou J, Palmore T, Irvine KR, Haeryfar SM, et al. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 2005;201(January(1)):95-104.
111. Mathew A, TerajimaM, West K, Green S, Rothman AL, Ennis FA, et al. Identification of murine poxvirus-specific CD8+ CTL epitopes with distinct functional profiles. J Immunol 2005;174(February(4)):2212-9.
112. Jing L, ChongTM, Byrd B, McClurkan CL, HuangJ, Story BT, et al. Dominance and diversity in the primary human CD4 T cell response to replication-competent vaccinia virus. J Immunol 2007;178(May(10)):6374-86.
113. Jing L, Chong TM, McClurkan CL, Huang J, Story BT, Koelle DM. Diversity in the acute CD8 T cell response to vaccinia virus in humans. J Immunol 2005;175(December(11)):7550-9.
114. Snyder JT, Belyakov IM, Dzutsev A, Lemonnier F, Berzofsky JA. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J Virol 2004;78(13):7052-60.
115. Kennedy R, Poland GA. T-Cell epitope discovery for variola and vaccinia viruses. Rev Med Virol 2007;17(March-April(2)):93-113.
116. Johnson KL, Ovsyannikova IG, Madden BJ, Poland GA, Muddiman DC. Accurate mass precursor ion data and tandem mass spectrometry identify a class I human leukocyte antigen A*0201-presented peptide originating from vaccinia virus. J Am Soc Mass Spectrom 2005;16(11):1812-7.
117. Ovsyannikova IG, Johnson KL,;1; Bergen 3rd HR, Poland GA. Mass spectrometry and peptide-based vaccine development. Clin Pharmacol Therapeut 2007;82(6):644-52.
118. Moise L, McMurry JA, Buus S, Frey S, Martin WD,;1; De Groot AS. In silicoaccelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes. Vaccine 2009;June.
119. Clark TG, Cassidy-Hanley D. Recombinant subunit vaccines: potentials and constraints. Develop Biol 2005;121:153-63.
120. Bielinska AU, Chepurnov AA, Landers JJ, Janczak KW, Chepurnova TS, Luker GD, et al. A novel, killed-virus nasal vaccinia virus vaccine. Clin Vaccine Immunol 2008;15(2):348-58.
121. Golovkin M, Spitsin S, Andrianov V, Smirnov Y, Xiao Y, Pogrebnyak N, et al. Smallpox subunit vaccine produced in Planta confers protection in mice. Proc Natl Acad Sci USA 2007;104(April(16)):6864-9.
122. Jahrling PB, Hensley LE, Martinez MJ, Leduc JW, Rubins KH, Relman DA, et al. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci USA 2004;101(October(42)):15196-200.
123. Crowe Jr JE. Genetic predisposition for adverse events after vaccination. J Infect Dis 2007;196(July(2)):176-7.
124. Stanley Jr SL, Frey SE, Taillon-Miller P, Guo J, Miller RD, Koboldt DC, et al. The immunogenetics of smallpox vaccination. J Infect Dis 2007;196(July(2)): 212-9.
125. Kennedy RB, Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Ryan MA, et al. Gender effects on humoral immune responses to smallpox vaccine. Vaccine 2009;27(May(25-26)):3319-23.
126. Poland GA. Pharmacology, vaccinomics, and the second golden age of vaccinology. Clin Pharmacol Therapeut 2007;82(6):623-6.
127. Sakhatskyy P, Wang S, Chou TH, Lu S. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology 2006;355(November(2)):164-74.
128. Pulford DJ, Gates A, Bridge SH, Robinson JH, Ulaeto D. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine 2004;22(September(25-26)):3358-66.